Faricimab Vision Gains, Disease Control Maintained at 48 Weeks

Patients with neovascular age-related macular degeneration (nAMD) treated with Faricimab, a bispecific angiopoietin-2/vascular endothelial growth factor (VEGF)-A inhibitor, sustained vision gains and decreases in central subfield thickness at 48 weeks, according to an analysis of 2 clinical trials. The research was presented at the 2022 annual meeting of the American Academy of Ophthalmology (AAO) held in Chicago, September 30 to October 3. 

The poster shows visual gains and disease control in 2 trials, TENYA (ClinicalTrials.gov Identifier: NCT03823287) and LUCERNE (ClinicalTrials.gov Identifier: NCT03823300), were continued during the maintenance phase in all faricimab dosing interval groups. The researchers assessed the 48-week efficacy of faricimab using data from 2 randomized, double-masked 112-week phase 3 trials, TENAYA (N=671) and LUCERNE (N=658). 

Both investigations randomly assigned patients to treatment with either faricimab 6 mg or aflibercept 2.0 mg. Faricimab patients were dosed once every 8 weeks (21%), once every 12 weeks (34%), or once every 16 weeks (45%) based on disease activity at weeks 20 and 24. Aflibercept was dosed once every 8 weeks.

All groups treated with faricimab, regardless of dosage, showed similar sustained vision gains and decreases in central subfield thickness (CST) during the maintenance phase between groups. Patients treated with faricimab on the once-every-16-weeks dosing interval maintained CST reductions after the initiation phase with minimal variation, the researchers report.